When Should We Use Nitrates in Congestive Heart Failure?

Cardiovascular Therapeutics

Volumn 31, Issue 1, 2013, Pages 27-31

  Vizzardi, Enrico ^a   Bonadei, Ivano ^a   Rovetta, Riccardo ^a   D'Aloia, Antonio ^a   Quinzani, Filippo ^a   Curnis, Antonio ^a   Dei Cas, Livio ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Heart failure; Nitrates

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIOXIDANT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ION; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FUROSEMIDE; GLYCERYL TRINITRATE; HYDRALAZINE PLUS ISOSORBIDE DINITRATE; ISOSORBIDE DINITRATE; ISOSORBIDE MONONITRATE; NESIRITIDE; NITRATE; NITROPRUSSIDE SODIUM; PLACEBO; PRAZOSIN; SPIRONOLACTONE;

ACUTE HEART FAILURE; CALCIUM CELL LEVEL; CARDIOVASCULAR MORTALITY; CONGESTIVE HEART FAILURE; CONTINUOUS INFUSION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; EARLY TERMINATION OF CLINICAL TRIAL; EXERCISE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE OXYGEN CONSUMPTION; HUMAN; LOW DRUG DOSE; LUNG EDEMA; NEW YORK HEART ASSOCIATION CLASS; POSITIVE END EXPIRATORY PRESSURE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPEATED DRUG DOSE; REVIEW; SURVIVAL; TREATMENT OUTCOME;

CARDIOTONIC AGENTS; CHRONIC DISEASE; HEART FAILURE; HEMODYNAMICS; HUMANS; MYOCARDIAL CONTRACTION; NITRATES; PRACTICE GUIDELINES AS TOPIC; TREATMENT OUTCOME; VASODILATOR AGENTS; VENTRICULAR FUNCTION;

EID: 84872335706     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/j.1755-5922.2012.00311.x     Document Type: Review

References (32)

1. Task Force for Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of European Society of Cardiology, Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, et al.; ESC Committee for Practice Guidelines, Vahanian A, Camm J, De Caterina R, Dean V, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008;29:2388-2442.
2. Jessup M, Abraham WT, Casey DE, et al. 2009 focused update: ACCF/AHA Guidelines for the diagnosis and management of heart failure in adults: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009;119:1977-2016.
3. Heart Failure Society of America, Lindenfeld J, Albert NM, et al. HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail 2010;16:e1-e194.
4. Ignarro LJ, Lippton H, Edwards JC, et al. Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites, nitroprusside and nitric oxide: Evidence for the involvement of S-nitrosothiols as active intermediates. J Pharmacol Exp Ther 1981;218:739-749.
5. De Caterina R, Dorso CR, Tack-Goldman K, et al. Nitrates and endothelial prostacyclin production: Studies in vitro. Circulation 1985;71:176-182.
6. Fung HL. Pharmacokinetic determinants of nitrate action. Am J Med 1984;76(Suppl 6A):22-26.
7. Abrams J. The role of nitrates in coronary heart disease. Arch Intern Med 1995;155:357-364.
8. Bauer JA, Booth BP, Fung HL. Nitric oxide donors: Biochemical pharmacology and therapeutics. Adv Pharmacol 1995;34:361-381.
9. Bode-Böger SM, Kojda G. Organic nitrates in cardiovascular disease. Cell Mol Biol 2005;51:307-320.
10. Elkayam U. Nitrates in the treatment of congestive heart failure. Am J Cardiol 1996;77:41C-51C.
11. Ludbrook PA, Byrne JD, Kurnik PB, Mcknight RC. Influence of reduction of preload and afterload by nitroglycerin on left ventricular diastolic pressure-volume relations in man. Circulation 1977;56:937-943.
12. Elkayam U, Roth A, Kumar A, et al. Hemodynamic and volumetric effects of venodilation with NTG in chronic mitral regurgitation. Am J Cardiol 1987;60:1106-1111.
13. Olivari MT, Carlyle PF, Levine TB, Cohn JN. Hemodinamic and hormonal response to transdermal nitroglycerin in normal subjects and in patients with congestive heart failure. J Am Coll Cardiol 1983;2:72-78.
14. Webster MW, Sharpe DN, Coxon R, et al. Effect of reducing atrial pressure on atrial natriuretic factor and vasoactive hormones in congestive heart failure secondary to ischemic and nonischemic dilated cardiomyopathy. Am J Cardiol 1989;63:217-221.
15. Dakak N, Makhoul N, Merdler A, et al. Haemodynamic and neurohumoral effects of flosequinan in severe heart failure: Similarities and differences compared with intravenous NTG therapy. Eur Heart J 1993;14:836-844.
16. Komajda M, Follath F, Swedberg K, et al. Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology. The EuroHeart Failure Survey programme-a survey on the quality of care among patients with heart failure in Europe. Part 2: Treatment. Eur Heart J 2003;24:464-474.
17. Fonarow GC. ADHERE Scientific Advisory Committee. The Acute Decompensated Heart Failure National Registry (ADHERE): Opportunities to improve care of patients hospitalized with acute decompensated heart failure. Rev Cardiovasc Med 2003;4(Suppl 7):S21-S30.
18. Cotter G, Metzkor E, Kaluski E, et al. Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema. Lancet 1998;351:389-393.
19. Sharon A, Shpirer I, Kaluski E, et al. High-dose intravenous isosorbide-dinitrate is safer and better than Bi-PAP ventilation combined with conventional treatment for severe pulmonary edema. J Am Coll Cardiol 2000;36:832-837.
20. Publication Committee for the VMAC [Vasodilatation in the Management of Acute CHF] Investigators. Intravenous nesiritide vs. nitroglycerin for treatment of decompensated congestive heart failure: A randomized controlled trial. JAMA 2002;287:1531-1540.
21. Elkayam U, Mehra A, Shotan A, Ostrzega E. Nitrate resistance and tolerance: Potential limitations in the treatment of congestive heart failure. Am J Cardiol 1992;70:98B-104B.
22. Breidthardt T, Noveanu M, Potocki M, et al. Impact of a high-dose nitrate strategy on cardiac stress in acute heart failure: A pilot study. J Intern Med. 2010;267:322-330.
23. Packer M, Lee WH, Kessler PD, Gottlieb SS, Medina N, Yushak M. Prevention and reversal of nitrate tolerance in patients with congestive heart failure. N Engl J Med 1987;317:799-804.
24. Roth A, Kulick D, Freidenberger L, Hong R, Rahimtoola SH, Elkayam U. Early tolerance to hemodynamic effects of high dose transdermal nitroglycerin in responders with severe chronic heart failure. J Am Coll Cardiol 1987;9:858-864.
25. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N Engl J Med 1991;325:293-302.
26. Packer M, O'Connor CM, Ghali JK, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 1996;335:1107-1114.
27. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997;336:525-533.
28. Bauer JA, Fung HL. Concurrent hydralazine administration prevents nitroglycerin-induced hemodynamic tolerance in experimental heart failure. Circulation 1991;84:35-39.
29. Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study (V-HeFT). N Engl J Med 1986;314:1547-1552.
30. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991;325:303-310.
31. Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004;351:2049-2057.
32. Mullens W, Abrahams Z, Francis GS, et al. Usefulness of Isosorbide Dinitrate and Hydralazine as add-on therapy in patients discharged for advanced decompensated heart failure. Am J Cardiol 2009;103:1113-1119.